MAX
Company Analysis Artelo Biosciences, Inc.
1. Summary
Advantages
- Price (1.2 $) is less than fair price (1.26 $)
- The stock's return over the last year (14.29%) is higher than the sector average (-43.9%).
Disadvantages
- Dividends (0%) are below the sector average (0.54%).
- Current debt level 1.34% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-134.52%) is lower than the sector average (ROE=104.5%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Artelo Biosciences, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -7.1% | -25.7% | -1.5% |
| 90 days | -38.5% | -49.5% | 0.7% |
| 1 year | 14.3% | -43.9% | 13.2% |
ARTL vs Sector: Artelo Biosciences, Inc. has outperformed the "Healthcare" sector by 58.18% over the past year.
ARTL vs Market: Artelo Biosciences, Inc. has outperformed the market by 1.09% over the past year.
Stable price: ARTL is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ARTL with weekly volatility of 0.27% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (1.2 $) is lower than the fair price (1.26 $).
Price not significantly lower than the fair price: The current price (1.2 $) is slightly lower than the fair price by 5%.
5.2. P/E
P/E vs Sector: The company's P/E (-3.34) is lower than that of the sector as a whole (33.29).
P/E vs Market: The company's P/E (-3.34) is higher than that of the market as a whole (-108).
5.3. P/BV
P/BV vs Sector: The company's P/BV (7.24) is lower than that of the sector as a whole (254.5).
P/BV vs Market: The company's P/BV (7.24) is lower than that of the market as a whole (83.29).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (129.32).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (115.88).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0.15) is higher than that of the sector as a whole (-27.64).
EV/Ebitda vs Market: The company's EV/Ebitda (0.15) is higher than that of the market as a whole (-92.19).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 6.56% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (6.56%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (241.72%).
6.4. ROE
ROE vs Sector: The company's ROE (-134.52%) is lower than that of the sector as a whole (104.5%).
ROE vs Market: The company's ROE (-134.52%) is lower than that of the market as a whole (-6.66%).
6.6. ROA
ROA vs Sector: The company's ROA (-110.77%) is lower than that of the sector as a whole (-2.18%).
ROA vs Market: The company's ROA (-110.77%) is lower than that of the market as a whole (37.94%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (1.04%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.38%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.54%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
